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Atrial fibrillation (AF) is the most common sustained arrhythmia, especially in the elderly,
and has a significant genetic component. Recently, several independent investigators
have demonstrated a functional role for small non-coding RNAs (microRNAs) in the
pathophysiology of this cardiac arrhythmia. This report represents a systematic and
updated appraisal of the main studies that established a mechanistic association between
specific microRNAs and AF, focusing both on the regulation of electrical and structural
remodeling of cardiac tissue.
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MicroRNA
MicroRNAs (miRs) are an evolutionarily conserved class of small
(∼22 nucleotides) non-coding RNAs (Ambros, 2004; Gan et al.,
2013), first discovered in Caenorhabditis elegans (Ruvkun and
Giusto, 1989; Ruvkun et al., 1989). They represent a vital com-
ponent of genetic regulation, existing in virtually all organisms,
suggesting thereby a pivotal role in biological processes (Latronico
and Condorelli, 2008; Thum et al., 2008). Indeed, miRs are
important regulators of gene expression in numerous biologi-
cal processes including cellular proliferation, differentiation, and
tumorigenesis (Care et al., 2007; Dvinge et al., 2013; Shen et al.,
2013; Song et al., 2013). Typically, miRs are regarded as nega-
tive regulators of gene expression that inhibit translation and/or
promote mRNA degradation by base pairing to complementary
sequences within the 3′-untranslated region (3′-UTR) of protein-
coding mRNA transcripts (Van Rooij and Olson, 2012; Meijer
et al., 2013). Generally, mRNA degradation accounts for the
majority of miR activity (Guo et al., 2010). Hence, by altering
levels of key regulators within complex genetic pathways, miRs
provide a posttranscriptional level of control of homeostatic and
developmental events (Callis et al., 2009; Yates et al., 2013).
It is estimated that miRs regulate over 60% of all protein-
coding genes (Friedman et al., 2009; Akerman and Mukherjee,
2013; Leucci et al., 2013). Considering that a single miR can reg-
ulate multiple mRNAs and that each mRNA may be a target of
multiple miRs, the possible pathways for miR-dependent regu-
lation of protein abundance seem to be extremely complicated
(Akerman and Mukherjee, 2013; Santulli and Totary-Jain, 2013).
In this model, a biologic response would be expected only after
co-expression of various miRs that cooperatively target different
components of a functional network (Liu et al., 2012; Van Rooij
and Olson, 2012) or are all required to sufficiently repress a single
target (Lagos-Quintana et al., 2001; Kim, 2013).
BIOGENESIS AND BIOLOGICAL ACTION OF miRs
Maturation of miRs involves a multi-stepped process (Bartel,
2004; Cullen, 2004) that starts from the transcription (mainly
operated by RNA polymerase II) of single-stranded non-protein-
coding RNAs, which are either transcribed as stand alone
transcripts (intergenic miRs), often encoding various miRs, or
generated by the processing of introns of protein-coding genes
(intragenic or intronic miRs).
Transcription of intergenic miRs leads to the formation of pri-
mary miRs (pri-miR) with a characteristic hairpin or stem-loop
structure (Denli et al., 2004), which are subsequently processed by
the nuclear RNase III, Drosha (Zeng et al., 2005), and its partner
proteins, among which there is the DiGeorge Syndrome Critical
Region 8 (DGCR8, known as Pasha in invertebrates), named for
its association with DiGeorge Syndrome (Shiohama et al., 2003;
Roth et al., 2013), to become precursor miR s (pre-miR). On the
other hand, intronic miRs are obtained by the regular transcrip-
tion of their host genes and then spliced to form looped pre-miRs,
bypassing thereby the Drosha pathway (Bartel, 2004; Ruby et al.,
2007).
Pre-miRs are exported from the nucleus in the cytoplasm in
a process involving the Ran-GTP-dependent shuttle Exportin-5
(Lund et al., 2004). Once in the cytosol, the pre-miR hairpin
is cleaved by the RNase III enzyme Dicer (Saxena and Tabin,
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2010; Marasovic et al., 2013), yielding a mature miR:miR* duplex
about 22 nucleotides in length, which is subsequently incorpo-
rated into the protein complex called RNA-induced silencing
complex (RISC) to form miRISC (Filipowicz et al., 2008; Wu
et al., 2013). At this point, one of the double strands, the guide
strand, is selected by the argonaute protein (Pfaff et al., 2013), the
catalytically active RNase in the RISC complex, on the basis of the
thermodynamic stability of the 5′ end. In particular, the strand
with a less thermodynamically stable 5′ end is commonly cho-
sen and loaded into the RISC complex (Siomi and Siomi, 2009),
serving as a guide for mRISC to find its complementary motifs
in the 3′-UTR of the target mRNA(s). Although either strand of
the mature duplex may potentially act as a functional miR, only
one strand is usually incorporated into the RISC where the miR
and its mRNA target interact (Fabian and Sonenberg, 2012; Von
Brandenstein et al., 2012). Such a binding inhibits the transla-
tion of the protein that the target mRNA encodes or promotes
gene silencing via mRNA degradation (Latronico and Condorelli,
2008; Kallen et al., 2012; Papait et al., 2013).
In the human genome more than 1200 miR sequences have
been identified, hitherto [miRTarBase, Release 4.5, version 20
(Hsu et al., 2011)], with over 50,000 miR-target interactions.
Recently, several algorithms and bioinformatics websites, includ-
ing TargetScan and miRWalk (Lewis et al., 2005; Dweep et al.,
2011) have been developed to predict specific mRNA/miR inter-
actions. However, miR-binding rules are quite complex and are
not fully understood, resulting in a lack of consensus in the
literature.
Given all these crucial features, miRs could represent an
important way for the cell to establish intercellular (with other
cells, via secreted miRs) and intracellular (among its own genes)
communication.
Establishing direct cause-and-effect links between miRs and
mRNA targets is essential to understanding the molecular mech-
anisms underlying disease and the subsequent development of
targeted therapies (Ambros et al., 2003; Zacharewicz et al., 2013).
ATRIAL FIBRILLATION
Atrial fibrillation (AF) is a highly prevalent disease with a sig-
nificant genetic component (Den Hoed et al., 2013; Mahida,
2013; Santulli, 2013), considered the most common sustained
arrhythmia, which can cause or exacerbate heart failure and
represents an important risk factor for ischemic stroke (Fye,
2006; Conen et al., 2011; Santulli, 2012b; Santulli et al., 2013;
Thomas and Sorrentino, 2014). AF represents the most com-
monly seen arrhythmia worldwide, especially in the geriatric
population (Huikuri, 2008; Riley and Manning, 2011; Santulli
et al., 2012c; Santulli and Iaccarino, 2013) and is associated with
a substantially pronounced morbidity and mortality (Beyerbach
and Zipes, 2004; Santulli, 2012a; Garg and Akoum, 2013;Menezes
et al., 2013). From a pathophysiological point of view, AF is char-
acterized by atrial electrical remodeling, mainly mediated by ion-
channel alterations (Brundel et al., 2001; Santulli et al., 2012b; Xie
et al., 2013) and structural remodeling (fibrosis and apoptosis),
which favors arrhythmia recurrence and maintenance (Perino
et al., 2011; Santulli and D’Ascia, 2012; Santulli et al., 2012b).
A noticeable feature of the electrical remodeling associated with
AF is the abbreviation of the effective refractory period favoring
reentry (D’Ascia et al., 2010, 2011; Kapur and Macrae, 2013),
primarily due to shortening of atrial action potential duration
(APD).
Three potential models have been proposed to explain the
pathophysiology of AF (Jalife, 2011), albeit the precise rela-
tionship of each of these conceptual frameworks to human AF
remains under investigation (Vikman et al., 2005; Kapur and
Macrae, 2013; Shah et al., 2013):
The focal mechanism theory suggests that AF is provoked
by the rapid firing of single or multiple ectopic foci, and also
proposes a functional role for continued ectopic firing in the
maintenance of AF (Lee et al., 2013).
The single circuit re-entry theory of AF assumes the presence
of a single dominant reentry circuit alongside with the fragmenta-
tion of emanating waves in the heterogeneous electrical substrate
of normal atrial tissue (Zemlin and Pertsov, 2007; Kapur and
Macrae, 2013).
The multiple wavelet theory of AF stands on the notion
that multiple reentry circuits exist, with randomly propagating
wavefronts that must find receptive tissue in order to persist
(Haissaguerre et al., 2013).
Slowing of conduction velocities and shortening of the refrac-
tory period of atrial myocytes (both central features of the electri-
cal remodeling seen in AF) might help to stabilize the arrhythmia
by decreasing circuit size. Of course these mechanistic models are
not mutually exclusive. They may coexist in a single subject at
various stages in the pathogenesis of AF and each may be appli-
cable to certain subgroups of AF patients (Lindgren et al., 2003;
Brieger and Freedman, 2009; Ruwald et al., 2013). Theoretically,
all the miRs that are directly or indirectly involved in one of these
processes, which are eventually based on the regulation of struc-
tural or electrical remodeling (cardiac automaticity, ion channels,
fibrosis, and apoptosis), could participate in AF induction or
perpetuation.
EXPERIMENTAL STRATEGY TO IDENTIFY miRs INVOLVED IN
HUMAN DISEASE
The most common experimental approach to identify the spe-
cific miRs that play a role in a certain disease mainly consists
of three phases: (1) Use a microarray matrix to recognize a list
of miRs that are differentially expressed in subjects with the dis-
ease compared to control subjects (Frezzetti et al., 2011; Jayaswal
et al., 2011); (2) assess the putative target site efficacy by using
bioinformatics-based algorithms or other computational tools
that score potential interactions betweenmicroRNAs andmRNAs
(Witkos et al., 2011); (3) validate in vitro (or in vivo) the existence
of an inverse correlation between the expression levels of the miR
and protein levels of its target gene(s). Another biological valida-
tion could be also achieved using a reporter system or other assays
to prove that the binding of the miR and the target mRNA occurs
within a RISC complex (Ling et al., 2013).
FUNCTIONAL ROLE OF miRs IN ATRIAL FIBRILLATION
Growing evidence demonstrates that miRs regulate several prop-
erties of cardiac physiology and excitability, including automatic-
ity, Ca2+ handling, conduction, and repolarization (Grueter et al.,
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2012; Boon et al., 2013; Heymans et al., 2013; Latronico and
Condorelli, 2013). In particular, recent reports have unveiled
an essential role of miRs in regulating cardiac excitability and
arrhythmogenesis (Callis et al., 2009; Shan et al., 2009). These
studies have primarily focused on the two muscle-specific miRs,
i.e., miR-1 and miR-133, which are among the most abundantly
expressed miRs in the heart (Liang et al., 2007; Wang et al., 2011).
However, lately other ubiquitously distributed miRs, such as
miR-328 have been shown to exhibit a strong arrhythmogenic
potential (Lu et al., 2010). It is likely thatmultiplemiRs contribute
to controlling arrhythmogenicity of the heart and that different
miRs are involved in different types of arrhythmias under dif-
ferent pathological conditions of the heart (Horie et al., 2012;
Kochegarov et al., 2013; Qiao et al., 2013; Zhang et al., 2013a).
The most important miRs so far implicated in the pathophysiol-
ogy of AF, regulating both electrical and structural remodeling,
are reported in Table 1, alongside with their target gene(s) and
function(s).
Although circulating miRs seem to be interesting candidates
as biomarkers in AF patients, they still possess several impor-
tant limitations (Quiat and Olson, 2013; Santulli and Totary-Jain,
2013). Indeed, at the moment there is no good natural stable
housekeeping control for circulating miRs, which may result in
strong variations, and they are generally present in low amounts
in plasma and serum.
REGULATION OF PROTEINS INVOLVED IN ELECTRICAL
REMODELING BY miRs
As mentioned above, arrhythmogenesis is essentially attributed
to enhanced triggered activity, and several studies have attributed
such activity to alterations in different ion channels, including
a peculiar instability in Ca2+ handling (Ter Keurs and Boyden,
2007; Zhang et al., 2008; Latronico and Condorelli, 2009; Kushnir
and Marks, 2010; Nivala et al., 2012) and modulation of the car-
diac inwardly rectifying K+ current (IK1), which stabilizes the
resting membrane potential, controls cardiac excitability, reg-
ulates late-phase repolarization, and is thereby responsible for
shaping the initial depolarization and final repolarization of the
action potential (Dhamoon and Jalife, 2005).
In a seminal study, the expression of miR-1 was demon-
strated to be reduced by ∼86% in tissue samples of AF patients
(Girmatsion et al., 2009). This miR has been shown to be mech-
anistically critical in the pathophysiology of AF via targeting IK1
and connexin43 (Girmatsion et al., 2009), both considered mas-
ter regulators of cardiac conduction (Delmar and Makita, 2012;
Musa et al., 2013). Similarly, miR-26 has the potential to repress
IK1 (Luo et al., 2013). Intriguingly, in the setting of ventricular
arrhythmias miR-1 levels appear to be augmented (Anderson and
Mohler, 2007; Yang et al., 2007). Thus, the different regulation of
such a miR in ventricular and atrial tissue deserves further inves-
tigations (Anderson and Mohler, 2007; Yang et al., 2007; Santulli
et al., 2012a). The recently proposed involvement of miR-1 in
the modulation of Ca2+ handling proteins, including calmodulin,
phospholamban, Na+/Ca2+ exchanger (NCX), sorcin, junctin,
triadin, eventually resulting in shortened refractoriness of sar-
coplasmic reticulum Ca2+ release further support the hypothesis
of a pivotal functional role of such a miR in the pathogenesis of
AF (Ali et al., 2012; Karakikes et al., 2013; Slagsvold et al., 2013;
Tritsch et al., 2013; Zhang et al., 2013b).
Lu et al. (2010) demonstrated that miR-328 level was ele-
vated in AF patients and identified as target genes CACNA1C
and CACNB1, encoding L-type Ca2+ channel subunits. Thereby,
increased levels of miR-328 reduce ICaL density and shorten APD,
leading to an increased arrhythmogenic potential. Additionally,
Table 1 | miRs with an established role in the regulation of cardiac electrical and structural remodeling.







Zhao et al., 2007;
Girmatsion et al., 2009
miR-21 Up-regulated Spry1, PDCD4 Inhibition of fibroblast proliferation Adam et al., 2012




Increased fibrosis Dawson et al., 2013
miR-30 Down-regulated CTGF Increased fibrosis Duisters et al., 2009
miR-133 Down-regulated CTGF, TGF-β Increased fibrosis Cooley et al., 2012
miR-328 Up-regulated CACNB1
CACNA1C
Shortened atrial action potential duration Lu et al., 2010
miR-499 Up-regulated KCNN3 Altered conduction Ling et al., 2013
AF, Atrial fibrillation; KCNJ2, K+ inwardly-rectifying channel, subfamily J, member 2; GJA1, Gap junction alpha1 protein; SPRY1, sprouty homolog 1; Mcl-2, Myeloid
cell-leukemia-2; CTGF, Connective tissue growth factor; TGF-β, Transforming growth factor β ; KCNN3, K+ intermediate/small conductance Ca2+-activated channel.
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miR-223, miR-328, and miR-664 were found to be upregulated by
>2 fold in AF samples (Lu et al., 2010), and further investigations
are required to establish the molecular mechanism underlying
such a change in the miR transcriptome.
Most recently, Ling and colleagues found a strong association
between mir-499, which is significantly up-regulated in atrial tis-
sue from AF patients, and KCNN3, the gene that encodes the
small-conductance Ca2+-activated K+ channel 3 (SK3), possi-
bly contributing to the electrical remodeling observed in AF
(Ling et al., 2013)
REGULATION OF PROTEINS INVOLVED IN STRUCTURAL
REMODELING BY miRs
Fibrosis is the hallmark of structural cardiac remodeling (Allessie
et al., 2002; Nguyen et al., 2013). Structural changes in the
atria of AF patients have been identified (Anyukhovsky et al.,
2005) at the level of cardiomyocytes and extracellular matrix
(ECM), which predominately includes collagen types I and III,
fibronectin, laminin, fibromodulin, and entactin (Goudis et al.,
2012). ECM remodeling represents a maladaptive response to
changes in myocardial structure and function during the pro-
gression of cardiac disease (Siwik and Colucci, 2004; Dernellis
and Panaretou, 2006). Degradation and deposition of ECM is
a process dynamically regulated by a delicate balance (Goudis
et al., 2012) between matrix metalloproteinases (MMPs) and
tissue inhibitors of matrix metalloproteinases (TIMPs).
In addition to the regulation of key proteins involved in elec-
trical remodeling, miR-1 also modulate cardiac fibrosis, through
means of its target protein Fibullin-2, a secreted protein impli-
cated in ECM remodeling (Karakikes et al., 2013). An intriguing
role for miR-21 and its downstream target Sprouty (Spry1), a
master regulator of fibroblast survival and growth factor secre-
tion, controlling the extent of interstitial fibrosis (Thum et al.,
2008), has been demonstrated both in AF patients, in which atria
miR-21 is increased, and murine models (Adam et al., 2012).
This miR might also be involved in the apoptosis process and in
inflammation (Ando et al., 2013). Several groups have recently
proposed miR-29 as a mechanistic contributor in AF, through
means a regulation of several proteins involved in cardiac fibrosis
and apoptosis (Straten and Andersen, 2010; Dawson et al., 2013;
Hale and Levis, 2013).
Another potential therapeutic target tomodulate fibrosis in AF
is miR-30, which expression is down-regulated in AF. This miR
directly interacts with the 3′ untranslated region of the connective
tissue growth factor (CTGF), a key profibrotic protein (Duisters
et al., 2009). The same group also proposedmiR-133 as a modula-
tor of CTGF protein levels (Duisters et al., 2009). Of interest, the
same miR-133, which levels are reduced in AF patients (Cooley
et al., 2012), is involved in the regulation of apoptosis and TGF-β
signaling (Goette, 2009).
CONCLUSIVE REMARKS
Mounting evidence demonstrates that miRs are becoming one of
the most fascinating areas of biology, given their critical roles in
fine-tuning of physiological processes and their deregulation in
several disorders, including AF. The relative role of different miRs
in AF may also depend on the underlying etiology of AF, as the
rhythm is an end stage manifestation of multiple, distinct pre-
disposing pathological changes. The functional role of miRs as
direct or indirect post-transcriptional regulators of genes implied
in electrical and/or structural remodeling strongly suggest that
these miRs may serve as potential biomarkers or promising drug
targets, in prevention, treatment, and management of AF.
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